Last reviewed · How we verify

NCT05092165: BLUE

Methylene Blue for the Prevention of Hypotension During Hemodialysis

Completed Phase 2 Last updated 17 April 2026
What this trial tests

Phase 2 trial testing Methylene Blue in Acute Kidney Injury in 261 participants. Completed in 16 December 2025.

Timeline
21 October 2021
Primary endpoint
16 December 2025
16 December 2025

Quick facts

Lead sponsorFederal University of São Paulo
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment261
Start date21 October 2021
Primary completion16 December 2025
Estimated completion16 December 2025
Sites1 location across Brazil

Drugs / interventions tested

Conditions studied

Sponsor

Federal University of São Paulo

Who can join

18 and older, any sex, with Acute Kidney Injury or Shock. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hypotension is a common complication of intermittent renal replacement therapy. Methylene blue, an inhibitor of nitric oxide synthesis, has been suggested to improve hemodynamics during renal replacement therapy in ambulatory patients, but evidence is lacking for critically ill patients. This trial will assess whether methylene blue can improve hemodynamics and blood pressure for patients with shock requiring renal replacement therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Methylene Blue

Trials testing the same drug.

Other recruiting trials for Acute Kidney Injury

Currently open trials in the same condition.

Other Federal University of São Paulo trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05092165.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing